SPDR S&P Biotech ETF (XBI)
Bay Colony Advisory Group Inc d b a Bay Colony Advisors Invests $793,000 in SPDR S&P Biotech ETF $XBI
Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new position in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 5,011 shares of the
Is State Street SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
The State Street SPDR S&P Biotech ETF (XBI) made its debut on 01/31/2006, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market.
ETF Showdown: XBI vs PBE, Which Biotech Fund Wins?
At first glance, SPDR S&P Biotech ETF (NYSEARCA:XBI) and Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) look like two flavors of the same bet on drug discovery.
Buying Biotech's Policy Discount With XBI And IBB: Most 'Feared' Nation Policy, Less-Than-Feared Damage
I initiate Buy ratings on SPDR S&P Biotech ETF and iShares Biotechnology ETF for 2026–2027, favoring XBI for higher upside. Biotech's rally reflects improving fundamentals: robust M&A, positive clinical data, improved financing, and more quantifiable policy risk, not indiscriminate multiple expansion. MFN drug-pricing risk is narrower than feared, with emerging policies fragmented by payer, product, geography, and voluntary manufacturer participation.
This ETF Is Up Nearly 17% in a Month and Doesn't Own a Single Share of Nvidia
Biotech is having a moment, and the numbers are hard to ignore. The SPDR S&P Biotech ETF (NYSEARCA:XBI) climbed 17.27% over the trailing month ending July 1, 2026, a run that would look right at home in the AI trade.
Should You Invest in the State Street SPDR S&P Biotech ETF (XBI)?
Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the State Street SPDR S&P Biotech ETF (XBI), a passively managed exchange traded fund launched on January 31, 2006.
Wall Street Technician Declares Financials, Industrials, and Biotech Poised for Breakouts. 3 ETFs Could Soar.
Markets are hunting for new leadership as the Big Tech engine sputters, and one Wall Street technician thinks she knows where the baton is being passed.
XBI: A "Hidden" ETF Up +70% In 1 Year.
State Street SPDR S&P Biotech ETF (XBI) has delivered over 75% 1-year performance, driven by equal-weight exposure to volatile small- and mid-cap biotech stocks. XBI's high beta profile offers strong upside in bullish healthcare cycles but exposes investors to elevated annualized volatility of around 26%. Current valuations for XBI are relatively stretched, with forward P/E at 17x and earnings growth expectations below 3%, making new entry less attractive.
‘Buying stuff like it's going out of fashion': Biotech M&A on track for best year since pre-Covid
So far in 2026, biotech deals amounted to $106 billion over 201 transactions, according to PitchBook data. That momentum in dealmaking comes despite an interest rate environment that has turned for the worse following the Iran war and inflationary impacts.
Is State Street SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
Making its debut on 01/31/2006, smart beta exchange traded fund State Street SPDR S&P Biotech ETF (XBI) provides investors broad exposure to the Health Care ETFs category of the market.
SPDR S&P Biotech ETF (XBI) Price Forecast: Long-Term Breakout Fuels Biotech Strength
XBI continues to strengthen following a multi-month breakout, with bullish trend signals supporting upside targets near key Fibonacci retracement resistance levels.
Deltec Asset Management LLC Invests $1.22 Million in SPDR S&P Biotech ETF $XBI
Deltec Asset Management LLC acquired a new position in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 10,000 shares of the exchange traded fund's stock, valued at approximately $1,219,000. A number of other hedge
Cwm LLC Buys 10,699 Shares of SPDR S&P Biotech ETF $XBI
Cwm LLC grew its stake in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) by 77.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 24,492 shares of the exchange traded fund's stock after acquiring an additional 10,699 shares
Should You Invest in the State Street SPDR S&P Biotech ETF (XBI)?
Launched on January 31, 2006, the State Street SPDR S&P Biotech ETF (XBI) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the equity market.
Greystone Financial Group LLC Buys Shares of 5,395 SPDR S&P Biotech ETF $XBI
Greystone Financial Group LLC purchased a new position in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) in the undefined quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 5,395 shares of the exchange traded fund's stock, valued at approximately $658,000. A number of other
Altfest L J & Co. Inc. Acquires 17,250 Shares of SPDR S&P Biotech ETF $XBI
Altfest L J and Co. Inc. boosted its stake in SPDR S&P Biotech ETF (NYSEARCA:XBI) by 13.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 142,171 shares of the exchange traded fund's stock after purchasing an additional
SPDR S&P Biotech ETF $XBI Shares Sold by Flagship Harbor Advisors LLC
Flagship Harbor Advisors LLC trimmed its position in SPDR S&P Biotech ETF (NYSEARCA:XBI) by 47.7% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 6,317 shares of the exchange traded fund's stock after selling 5,756 shares during the period. Flagship Harbor Advisors LLC's holdings
Ascent Group LLC Buys New Position in SPDR S&P Biotech ETF $XBI
Ascent Group LLC bought a new stake in SPDR S&P Biotech ETF (NYSEARCA:XBI) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 3,883 shares of the exchange traded fund's stock, valued at approximately $473,000. Other institutional investors and hedge funds have
4,020 Shares in SPDR S&P Biotech ETF $XBI Acquired by Apella Capital LLC
Apella Capital LLC purchased a new position in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 4,020 shares of the exchange traded fund's stock, valued at approximately $490,000. Other large investors
XBI vs. IBB: The Biotech ETF Showdown That Analysts Say Has a Clear Winner in 2026
Biotech has long been one of the strongest sector stories of the past year, and investors who got there early have been rewarded.